Ginkgo Bioworks (DNA) announced a new collaboration with Merck (MRK) focused on improving biologic manufacturing. Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterization and process optimization to improve production efficiency and increase yields. Under the terms of the collaboration, Ginkgo is eligible to receive, in aggregate, up to $490M in upfront research fees, research milestone fees, option license payments and commercial milestone payments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks, government of Panama enter MoU
- Ginkgo Bioworks awarded $18M contract by DARPA
- Ginkgo Bioworks, Sumitomo Chemical announce expanded partnership
- Ginkgo Bioworks, MoH of Botswana pathogen monitoring program at key ports
- Ginkgo Bioworks awarded research contract for biointelligence and biosecurity